Theragnostics Pipeline

Theragnostics proprietary clinical lead, THG-001 (THP-PSMA), is being developed with our Galli® technology to provide valuable diagnostic information on the status of patients with prostate cancer.

A Phase I clinical trial of THG-001 was completed during 2016 results of the trial have been published in the Journal of Nuclear Medicine.

Theragnostics Pipeline
Representative images from the Phase I study of THG-001
(THP-PSMA)